Dr. John Öhd appointed Chief Medical Officer at Modus Therapeutics

STOCKHOLM, SWEDEN –15 March 2018: Modus Therapeutics AB, a company developing innovative treatments in disease areas with high unmet medical needs with a focus on sickle cell disease (SCD), announces the appointment of Dr. John Öhd as the Company’s Chief Medical Officer (CMO).

Dr. Öhd joins Modus from Medivir AB, where he was CMO and a member of the company’s Executive Management team. Before taking up his current position, John was Medivir’s Director of Clinical R&D. Prior to joining Medivir, John was senior director of Experimental Medicine at Shire based in Nyon, Switzerland.  Between 2007 and 2012, Dr. Öhd held several positions of increasing responsibility at AstraZeneca in Södertalje, Sweden.

In his early career, John worked in cancer research, initially at Lund University, where he received a PhD in Experimental Pathology and subsequently at Karolinska Institute. John received his MD from Linköping University, and trained clinically at Karolinska University Hospital.

Ellen K. Donnelly, Chief Executive of Modus Therapeutics, commented:

“We are delighted that we have been able to attract someone of John’s calibre as our new CMO. John not only has extensive clinical development experience, but he brings to Modus important prior experience working on sickle cell disease (SCD) at Shire. I am looking forward to John’s contributions as we continue development of sevuparin in SCD with the aim of creating a subcutaneous formulation.  This new formulation will enable SCD patients to lead more normal lives by reducing the need for hospital administration for the treatment of painful vaso-occlusive crises (VOCs).  John’s expertise will be a strong complement to our existing team and will ensure that Modus is well positioned for our next phase of development.”

Dr. John Öhd, Modus Therapeutics’ new Chief Medical Officer (CMO) said:

“I am excited to join Modus to help the company develop sevuparin, a novel treatment being developed for SCD and a number of other indications. In the short term our focus is on completing the on-going Phase II study which is looking to show that sevuparin can address the underlying cause of the VOCs experienced by SCD patients. The trial is designed to demonstrate that sevuparin is safe and well tolerated and can provide earlier pain relief, a reduced need for opioids, shorter hospital stays and, as a result, improve the patient’s quality of life.”

 

For further information, please contact:
Ellen K Donnelly, CEO, Modus Therapeutics:

Tel: +46 70 246 7554

E-mail: ellen.donnelly@modustx.com

 

David Dible/ Pip Batty, Citigate Dewe Rogerson

Tel: +44 20 7638 9571

E-mail: david.dible@citigatedewerogerson.com

 

 

FOR THE EDITORS

About Modus Therapeutics AB

Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) and Malaria.  Sevuparin is currently being tested in a Phase II clinical study for SCD – a painful, inherited blood disorder affecting millions of people around the globe. SCD patients’ blood cells form a sickled shape, which makes blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients’ blood flow reducing their pain and the amount of time they will need to spend in hospital. Modus plans to develop an administration form of sevuparin that the patient can self-administer allowing them to live a more normal life by preventing the painful episodes requiring hospital care.

Modus is predominantly owned by KDev Investments AB, part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital. Other larger owners are The Foundation for Baltic and European Studies (Östersjöstiftelsen) and Praktikerinvest AB. For more information, please visit www.modustx.com

 

About sevuparin

Sevuparin is an innovative, proprietary polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action.  Sevuparin has the potential to restore blood flow and prevent further microvascular obstructions in a number of diseases including SCD and malaria.  In SCD, the anti-adhesive effects of sevuparin could thereby offer treatment of the underlying cause of vaso-occlusive crisis (VOC) in SCD patients, with earlier pain relief, shorter hospital stays, reduced need of opioids and improved quality of life. Modus is currently enrolling patients in a Phase II study with the aim to complete the study in late 2018.

 

About sickle cell disease

Sickle cell disease (SCD) is a painful, inherited blood disorder affecting millions of people around the globe and the most common inherited blood disorder in the U.S. affecting between 90,000-100,000 subjects, with medical care costs amounting to more than $1 billion. In Europe it is estimated that there are 35,000-40,000 SCD patients, with an even higher number in the Middle East and North Africa regions, with over 850,000 SCD patients.

There is currently no pharmaceutical product available that targets the underlying cause of VOCs that affect SCD patients. Current therapies are predominantly strong intravenous pain medications and SCD patients often have to be hospitalized in order to be treated.